Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease
Cambridge, Mass. and Burnaby, British Columbia , June 06, 2022 (GLOBE NEWSWIRE) — Biogen and…